Product Description
Gilead is developing GS4528 as a mono/combo (+ ANTI PD1) for the treatment of Solid Tumors. (Sourced from: https://clinicaltrials.gov/study/NCT05840224)
Mechanisms of Action: IL2 Inhibitor
Novel Mechanism: No
Modality: Fusion Protein
Route of Administration: Intravenous
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Gilead Sciences
Company Location: Western America
Company Founding Year: 1987
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: Canada, South Korea, Spain, Taiwan, United Kingdom, United States
Active Clinical Trial Count: 1
Recent & Upcoming Milestones
Highest Development Phases
Phase 1: Oncology Solid Tumor Unspecified
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT05840224 |
GS-US-616-6291 | P1 |
Active, not recruiting |
Oncology Solid Tumor Unspecified |
2026-07-01 |
50% |
2026-01-29 |
Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments |
Recent News Events
Date |
Type |
Title |
|---|